Skip to Content
Merck
  • A20 haploinsufficiency disturbs immune homeostasis and drives the transformation of lymphocytes with permissive antigen receptors.

A20 haploinsufficiency disturbs immune homeostasis and drives the transformation of lymphocytes with permissive antigen receptors.

Science advances (2024-08-21)
Christoph Schultheiß, Lisa Paschold, Alma Nazlie Mohebiany, Moritz Escher, Yogita Mallu Kattimani, Melanie Müller, Paul Schmidt-Barbo, Anna Mensa-Vilaró, Juan Ignacio Aróstegui, Guilaine Boursier, Claire de Moreuil, Timo Hautala, Edith Willscher, Hanna Jonas, Namuun Chinchuluun, Bianca Grosser, Bruno Märkl, Wolfram Klapper, Prasad Thomas Oommen, Katharina Gössling, Katrin Hoffmann, Gisa Tiegs, Felix Czernilofsky, Sascha Dietrich, Alexandra Freeman, Daniella M Schwartz, Ari Waisman, Ivona Aksentijevich, Mascha Binder
ABSTRACT

Genetic TNFAIP3 (A20) inactivation is a classical somatic lymphoma lesion and the genomic trait in haploinsufficiency of A20 (HA20). In a cohort of 34 patients with HA20, we show that heterozygous TNFAIP3 loss skews immune repertoires toward lymphocytes with classical self-reactive antigen receptors typically found in B and T cell lymphomas. This skewing was mediated by a feed-forward tumor necrosis factor (TNF)/A20/nuclear factor κB (NF-κB) loop that shaped pre-lymphoma transcriptome signatures in clonally expanded B (CD81, BACH2, and NEAT1) or T (GATA3, TOX, and PDCD1) cells. The skewing was reversed by anti-TNF treatment but could also progress to overt lymphoma. Analysis of conditional TNFAIP3 knock-out mice reproduced the wiring of the TNF/A20/NF-κB signaling axis with permissive antigen receptors and suggested a distinct regulation in B and T cells. Together, patients with the genetic disorder HA20 provide an exceptional window into A20/TNF/NF-κB-mediated control of immune homeostasis and early steps of lymphomagenesis that remain clinically unrecognized.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Goat Anti-Mouse IgM µ chain Antibody, Species Adsorbed, 1 mg/mL, Chemicon®
Sigma-Aldrich
(Z)-4-Hydroxytamoxifen, ≥98% Z isomer